{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:58:06Z","timestamp":1788195486458,"version":"build-2803163510"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Calcium pyrophosphate deposition (CPPD) disease is a form of crystal-induced arthropathy that arises from the accumulation of calcium pyrophosphate crystals within joints and soft tissues. This process leads to inflammation and damage to the affected joints. It can present asymptomatically or as acute or chronic inflammatory arthritis. Risk factors and comorbidities, including prior joint injury, osteoarthritis, hereditary or familial predisposition, and metabolic diseases, should be evaluated in CPPD cases. The management of CPPD remains a challenge in the sparsity of randomized controlled trials. The lack of such trials makes it difficult to establish evidence-based treatment protocols for CPPD. This review provides an overview of the current pharmacological management of CPPD, focusing on reducing inflammation, alleviating symptoms, and preventing acute flares. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine are effective in managing acute CPP arthritis. Colchicine may also be used prophylactically to prevent recurrent flares. In cases where other treatments have failed, anakinra, an interleukin-1 receptor antagonist, can be administered to alleviate acute flares. The management of chronic CPP inflammatory arthritis includes NSAIDs and\/or colchicine, followed by hydroxychloroquine, low-dose glucocorticoids, and methotrexate, with limited data on efficacy. Tocilizumab can be used in refractory cases. In small studies, synovial destruction using intra-articular injection of yttrium 90 can decrease pain. To date, no disease-modifying therapies exist that reduce articular calcification in CPPD.<\/jats:p>","DOI":"10.3389\/fmed.2024.1327715","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:47:35Z","timestamp":1710118055000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Recent advances in the therapeutic management of calcium pyrophosphate deposition disease"],"prefix":"10.3389","volume":"11","author":[{"given":"Paraskevi V.","family":"Voulgari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliki I.","family":"Venetsanopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros A.","family":"Drosos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"ref1","article-title":"Calcium pyrophosphate deposition disease","volume-title":"StatPearls","author":"Zamora","year":"2023"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/ard.2010.139105","article-title":"European league against rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40744-022-00426-z","article-title":"A patient with symmetrical polyarthritis. The value of conventional radiography for a correct diagnosis","volume":"9","author":"Drosos","year":"2022","journal-title":"Rheumatol Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1177\/1071100714560399","article-title":"Destructive pseudo-neuroarthropathy associated with calcium pyrophosphate deposition","volume":"36","author":"Lomax","year":"2015","journal-title":"Foot Ankle Int"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/rheumatology\/keh370","article-title":"Crowned dens syndrome misdiagnosed as polymyalgia rheumatica, giant cell arteritis, meningitis or spondylitis: an analysis of eight cases","volume":"43","author":"Aouba","year":"2004","journal-title":"Rheumatology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"101718","DOI":"10.1016\/j.berh.2021.101718","article-title":"Pathogenesis of calcium pyrophosphate deposition disease","volume":"35","author":"Williams","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/00002281-200305000-00020","article-title":"Metabolism of extracellular pyrophosphate","volume":"15","author":"Ryan","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"ref8","first-page":"1108","article-title":"Association between crystals and cartilage degeneration in the ankle","volume":"35","author":"Muehleman","year":"2008","journal-title":"J Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/BOR.0000000000000246","article-title":"Calcium pyrophosphate deposition disease: a review of epidemiologic findings","volume":"28","author":"Abhishek","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11926-015-0496-1","article-title":"Imaging of calcium pyrophosphate deposition disease","volume":"17","author":"Miksanek","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/acr.24898","article-title":"Imaging features of calcium pyrophosphate deposition disease: consensus definitions from an international multidisciplinary working group","volume":"75","author":"Tedeschi","year":"2023","journal-title":"Arthritis Care Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/BOR.0000000000000939","article-title":"How can ultrasonography help in the management of CPPD? From diagnosis to clinical subset identification","volume":"35","author":"Filippou","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1136\/ard-2023-224575","article-title":"The 2023 ACR\/EULAR classification criteria for calcium pyrophosphate deposition disease","volume":"82","author":"Abhishek","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/ard.2010.139360","article-title":"EULAR recommendations for calcium pyrophosphate deposition. Part II: management","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.semarthrit.2020.10.005","article-title":"Management of calcium pyrophosphate crystal deposition disease: a systematic review","volume":"51","author":"Parperis","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e3840","DOI":"10.7759\/cureus.3840","article-title":"Updated treatment for calcium pyrophosphate deposition disease: an insight","volume":"11","author":"Iqbal","year":"2019","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.ijom.2020.07.029","article-title":"Arthroscopic diagnosis and medical management of calcium pyrophosphate deposition disease in the temporomandibular joint","volume":"49","author":"Choi","year":"2020","journal-title":"Int J Oral Maxillofac Surg"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1055\/s-0034-1370897","article-title":"Retro-odontoid calcium pyrophosphate dehydrate deposition: surgical management and review of the literature","volume":"5","author":"Klineberg","year":"2014","journal-title":"Evid Based Spine Care J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.rdc.2014.01.010","article-title":"Non-pharmacologic and pharmacologic management of CPP crystal arthritis and BCP arthropathy and periarticular syndromes","volume":"40","author":"Rosenthal","year":"2014","journal-title":"Rheum Dis Clin N Am"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"CD010120","DOI":"10.1002\/14651858.CD010120.pub3","article-title":"Non-steroidal anti-inflammatory drugs for acute gout","volume":"12","author":"van Durme","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.2147\/JPR.S247781","article-title":"Practice advisory on the appropriate use of NSAIDs in primary care","volume":"13","author":"Ho","year":"2020","journal-title":"J Pain Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine--update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/art.1780230917","article-title":"Colchicine and pseudogout","volume":"23","author":"Spilberg","year":"1980","journal-title":"Arthritis Rheum"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/art.1780230320","article-title":"Intravenous colchicine in the treatment of acute pseudogout","volume":"23","author":"Tabatabai","year":"1980","journal-title":"Arthritis Rheum"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref26","volume-title":"Drug products containing colchicine for injection; enforcement action dates. A notice by the Food and Drug Administration on 02\/08\/2008. Federal Register. [Docket No. FDA\u20132007\u2013D\u20130369]","year":""},{"key":"ref27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/RHU.0b013e3182056042","article-title":"Colchicine-induced rhabdomyolysis in a heart\/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin","volume":"17","author":"Bouqui\u00e9","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/phar.2674","article-title":"A systematic review of the drug-drug interaction between statins and colchicine: patient characteristics, etiologies, and clinical management strategies","volume":"42","author":"Schwier","year":"2022","journal-title":"Pharmacotherapy"},{"key":"ref29","volume-title":"Medication guide revision 02 September 2009 mutual pharmaceutical","year":""},{"key":"ref30","first-page":"804","article-title":"Colchicine prophylaxis in pseudogout","volume":"13","author":"Alvarellos","year":"1986","journal-title":"J Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/art.1780251226","article-title":"Colchicine and pseudogout","volume":"25","author":"Gonz\u00e1lez","year":"1982","journal-title":"Arthritis Rheum"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/art.10455","article-title":"A randomized controlled trial to evaluate the slow-acting symptom-modifying effects of colchicine in osteoarthritis of the knee: a preliminary report","volume":"47","author":"Das","year":"2002","journal-title":"Arthritis Rheum"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1016\/S2665-9913(23)00165-0","article-title":"Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial","volume":"5","author":"Pascart","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"ref34","article-title":"Corticosteroids","volume-title":"StatPearls","author":"Hodgens","year":"2023"},{"key":"ref35","first-page":"1168","article-title":"Prospective use of intramuscular triamcinolone acetonide in pseudogout","volume":"24","author":"Roane","year":"1997","journal-title":"J Rheumatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jbspin.2013.05.006","article-title":"ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients","volume":"81","author":"Daoussis","year":"2014","journal-title":"Joint Bone Spine"},{"key":"ref37","first-page":"696","article-title":"ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems","volume":"21","author":"Ritter","year":"1994","journal-title":"J Rheumatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.4049\/jimmunol.152.11.5485","article-title":"Crystal-induced neutrophil activation. V. Differential production of biologically active IL-1 and IL-1 receptor antagonist","volume":"152","author":"Roberge","year":"1994","journal-title":"J Immunol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1007\/s11033-021-06457-z","article-title":"The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease","volume":"48","author":"Altomare","year":"2021","journal-title":"Mol Biol Rep"},{"key":"ref40","first-page":"1001","article-title":"Biologics in the treatment of calcium pyrophosphate deposition disease: a systematic literature review","volume":"38","author":"Cipolletta","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11926-018-0739-z","article-title":"Therapy for CPPD: options and evidence","volume":"20","author":"Andr\u00e9s","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/art.23119","article-title":"Successful treatment of resistant pseudogout with anakinra","volume":"58","author":"McGonagle","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jbspin.2009.01.001","article-title":"Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure","volume":"76","author":"Announ","year":"2009","journal-title":"Joint Bone Spine"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jbspin.2011.12.017","article-title":"Efficacy of anakinra in articular chondrocalcinosis: report of three cases","volume":"79","author":"Couderc","year":"2012","journal-title":"Joint Bone Spine"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jbspin.2012.01.010","article-title":"Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis","volume":"79","author":"Molt\u00f3","year":"2012","journal-title":"Joint Bone Spine"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/RHU.0b013e31826149a2","article-title":"Interleukin 1\u03b2 blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment","volume":"18","author":"Diamantopoulos","year":"2012","journal-title":"J Clin Rheumatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jbspin.2012.07.018","article-title":"Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature","volume":"80","author":"Ottaviani","year":"2013","journal-title":"Joint Bone Spine"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"792173","DOI":"10.1155\/2015\/792173","article-title":"Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature","volume":"2015","author":"Aouba","year":"2015","journal-title":"Mediat Inflamm"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3899\/jrheum.180393","article-title":"Utility of Anakinra in acute crystalline diseases: a retrospective study comparing a university hospital with a veterans affairs medical center","volume":"46","author":"Desmarais","year":"2019","journal-title":"J Rheumatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10067-018-4272-2","article-title":"Efficacy and tolerance of anakinra in acute calcium pyrophosphate crystal arthritis: a retrospective study of 33 cases","volume":"38","author":"Thomas","year":"2019","journal-title":"Clin Rheumatol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3899\/jrheum.181018","article-title":"Use of Anakinra in hospitalized patients with crystal-associated arthritis","volume":"46","author":"Liew","year":"2019","journal-title":"J Rheumatol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"105088","DOI":"10.1016\/j.jbspin.2020.105088","article-title":"Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: a randomized controlled double-blinded pilot study","volume":"88","author":"Dumusc","year":"2021","journal-title":"Joint Bone Spine"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e0261940","DOI":"10.1371\/journal.pone.0261940","article-title":"Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients","volume":"17","author":"van de Laar","year":"2022","journal-title":"PLoS One"},{"key":"ref54","first-page":"327","article-title":"Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD","volume":"23","author":"Rothschild","year":"1997","journal-title":"Compr Ther"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/art.22389","article-title":"Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis","volume":"56","author":"Chollet-Janin","year":"2007","journal-title":"Arthritis Rheum"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/RHU.0b013e3182611471","article-title":"Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis","volume":"18","author":"Andres","year":"2012","journal-title":"J Clin Rheumatol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s13075-014-0458-4","article-title":"Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial","volume":"16","author":"Finckh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-015-0598-1","article-title":"Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease?","volume":"17","author":"Pascual","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"101720","DOI":"10.1016\/j.berh.2021.101720","article-title":"Calcium pyrophosphate deposition (CPPD) disease - treatment options","volume":"35","author":"Stack","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/RHU.0b013e3180690c75","article-title":"Development of pseudogout during etanercept treatment","volume":"13","author":"Josefina","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbspin.2017.04.008","article-title":"Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: two cases report","volume":"85","author":"Quilis","year":"2018","journal-title":"Joint Bone Spine"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1136\/annrheumdis-2020-217188","article-title":"Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study","volume":"79","author":"Latourte","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref63","first-page":"3","article-title":"Effects of glycosaminoglycan polysulphate in the treatment of chondrocalcinosis","volume":"6","author":"Sarkozi","year":"1988","journal-title":"Clin Exp Rheumatol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1002\/1529-0131(199906)42:6<1302::AID-ANR33>3.0.CO;2-4","article-title":"Recurrent acute calcium pyrophosphate dihydrate arthritis following intraarticular hyaluronate injection","volume":"42","author":"Disla","year":"1999","journal-title":"Arthritis Rheum"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/1529-0131(199805)41:5<939::AID-ART24>3.0.CO;2-D","article-title":"Pseudogout following intraarticular injection of sodium hyaluronate","volume":"41","author":"Luzar","year":"1998","journal-title":"Arthritis Rheum"},{"key":"ref66","first-page":"593","article-title":"Acute attack of chondrocalcinosis after an intraarticular injection of hyaluronan","volume":"64","author":"Maillefert","year":"1997","journal-title":"Rev Rhum Engl Ed"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/1529-0131(200007)43:7<1657::AID-ANR37>3.0.CO;2-4","article-title":"Pseudogout and intraarticular hyaluronate injections: comment on the article by Disla et al","volume":"43","author":"Punzi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1136\/annrheumdis-2019-eular.8160","article-title":"AB0862 efficacy and safety of US-guided injections of the knees with hyaluronic acid in patients affected by osteoarthritis associated to calcium pyrophosphate deposition disease: preliminary results","volume":"78","author":"Adinolfi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/s0140-6736(81)91488-4","article-title":"Effect of intra-articular yttrium-90 on chronic pyrophosphate arthropathy of the knee","volume":"2","author":"Doherty","year":"1981","journal-title":"Lancet"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1089\/pho.2006.24.140","article-title":"Photobiomodulation of pain and inflammation in microcrystalline arthropathies: experimental and clinical results","volume":"24","author":"Soriano","year":"2006","journal-title":"Photomed Laser Surg"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/ard.42.Suppl_1.106","article-title":"Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy","volume":"42","author":"Doherty","year":"1983","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1327715\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:47:47Z","timestamp":1710118067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1327715\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":71,"alternative-id":["10.3389\/fmed.2024.1327715"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1327715","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"article-number":"1327715"}}